Browse studies

Find your next paid study

10 recruiting studies matching your filters

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition cal…

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Estimated

~$10 – $7,500

Novo Nordisk A/SNCT07207811

Identifying Subclinical Transthyretin Cardiac Amyloidosis in Asymptomatic Carriers of the V122I TTR Allele

Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the tr…

Amyloidosis, HereditaryAmyloidosis CardiacAmyloidosis, Familial+2 more

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT05489549

Phase 3

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated …

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07789483

A Multicenter Pilot Study to Investigate Ocular Involvement and the Potential of Ocular Imaging for Non-invasive Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart fai…

Transthyretin Amyloid Cardiomyopathy

Estimated

~$10 – $1,125

AstraZenecaNCT07690436

Phase 3

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like subs…

AmyloidosisAmyloid CardiomyopathyTransthyretin Amyloidosis+3 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT06563895

Phase 4

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy+1 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT07695701

Observational

Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis

Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training progra…

Amyloid CardiomyopathyTransthyretin Cardiac Amyloidosis

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT05797857

Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with lev…

Transthyretin (TTR) Amyloid Cardiomyopathy

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT07196839

Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study

The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failu…

HFpEF - Heart Failure With Preserved Ejection FractionHFmrEFATTR-CM (Transthyretin Amyloid Cardiomyopathy)+2 more

Estimated

~$10 – $1,125

eMyosound SASNCT07215715

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patie…

Alpha-ThalassemiaBeta-ThalassemiaAmyloidosis+14 more

Estimated

~$10 – $1,125

xCuresNCT06539169